(Q40941480)

25 September 2017

1 reference

title

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure (English)

1 reference

25 September 2017

main subject

congestive heart failure

1 reference

Awan NA

1

1 reference

25 September 2017

Mason DT

series ordinal

2

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

25 September 2017

published in

American Heart Journal

1 reference

25 September 2017

volume

131

1 reference

25 September 2017

issue

1

1 reference

25 September 2017

page(s)

177-185

1 reference

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Converting enzyme inhibition with an orally active compound in hypertensive man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Medical intelligence drug therapy: captopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Captopril in various forms of severe therapy-resistant hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Comparison of the antihypertensive efficiency of nitrendipine, metoprolol, mepindolol and enalapril using ambulatory 24-hour blood pressure monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Identification of angiotensin II receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Discrimination of angiotensin II receptor subtypes by dithiothreitol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Renin-angiotensin system: biochemistry and mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Angiotensin II receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Binding characteristics and vascular effects of various angiotensin II antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Effect of angiotensin II antagonism on canine renal sympathetic nerve function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Effects of DuP 753 on Proximal Nephron and Renal Transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

A specific competitive antagonist of the vascular action of angiotensin. II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

DuP 753 is a specific antagonist for the angiotensin receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Clinical Experience With Angiotensin II Receptor Antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Use of an Angiotensin II Antagonist (Saralasin) in the Recognition of “Angiotensinogenic” Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Neurohumoral control mechanisms in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

Angiotensin II Receptor Heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

7 January 2021

The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

7 January 2021

In Vitro Pharmacology of DuP 753

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

7 January 2021

Effects of the Nonpeptide Angiotensin II Receptor Antagonist DuP 753 on Blood Pressure and Renal Functions in Spontaneously Hypertensive PH Dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990067-8

7 January 2021

10.1016/S0002-8703(96)90067-8

Identifiers

DOI

1 reference

25 September 2017

1 reference